{
    "clinical_study": {
        "@rank": "89077", 
        "acronym": "APER\u00c7U", 
        "arm_group": [
            {
                "arm_group_label": "Complete Remission", 
                "description": "Complete remission arm in mRCC patients treated with sunitinib."
            }, 
            {
                "arm_group_label": "Non Complete Remission", 
                "description": "Non complete remission arm in mRCC patients treated with sunitinib."
            }
        ], 
        "biospec_descr": {
            "textblock": "whole blood and serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This prospective study will investigate the characteristics of mRCC patients at time of CR\n      in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some\n      answers/ refection leads to the following questions :\n\n      Can we identify blood specificity at time of CR vs non on CR? Shall we distinguish CR with\n      sunitinib alone from combined CR (sunitinib with local treatment), while in clinical report\n      these 2 cohorts present similar time to recurrence (ALBIGES, ASCO 2010)? Can we identify\n      potential predictive serum biomarkers of recurrence? (With the aim of isolating blood\n      biomarker that can help on treatment discontinuation decision?)"
        }, 
        "brief_title": "Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Complete Remission in Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The main objective of the study is to describe the characteristics of mRCC patients on CR\n      with Sunitinib (Cases) and compare them to the characteristics of mRCC patients non on CR\n      (controls) in order to identify factors associated with the occurrence of complete\n      remission.\n\n      The results obtained on the sample must be representative of the population targeted by the\n      study. The most appropriate method to obtain a representative sample is probability\n      sampling.\n\n      A sample size of N = 40 (cases) and  N = 80 (Controls) will provide a power of 80% in the\n      detection of a frequency difference between cases and controls corresponding to an OR of\n      0.24 for a parameter frequency 10% in control arm and an OR of 0.30 for a parameter\n      frequency of around 30% in control arm. The significance level was set at bilateral 5%.\n\n      The data will be analyzed using SAS software (version 9.1 - SAS Institute, North Carolina,\n      United States)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with metastatic renal cell carcinoma, histopathologically confirmed\n\n          -  Treated with sunitinib according to Smpc\n\n          -  For cases: Achieving a CR (local assessment according to RECIST V1.0 criteria) with\n             Sunitinib in prior 6 months alone OR in combination with local treatment (surgery,\n             radiation therapy, ablative techniques: cryotherapy, RFA)\n\n          -  For controls: Life expectancy > 3 months No prior Sunitinib treatment\n\n          -  Patient >18 years\n\n        Exclusion Criteria:\n\n          -  Sunitinib administered in a non-approved label\n\n          -  For cases: CR occurring without sunitinib treatment\n\n          -  For controls: Prior systemic treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "complete remission in mRCC patients treated with sunitinib versus non complete remission\n        in mRCC patients treated with sunitinib"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934452", 
            "org_study_id": "NRA6180080"
        }, 
        "intervention": [
            {
                "arm_group_label": "Complete Remission", 
                "description": "50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off  for 6 months", 
                "intervention_name": "sunitinib", 
                "intervention_type": "Drug", 
                "other_name": "Cases"
            }, 
            {
                "arm_group_label": "Non Complete Remission", 
                "description": "50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off  for 6 months", 
                "intervention_name": "sunitinib", 
                "intervention_type": "Drug", 
                "other_name": "Controls"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "complete remission", 
        "lastchanged_date": "May 28, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=NRA6180080&StudyName=Prospective%20Observational%20Analysis%20Of%20CR%20With%20Sunitinib%20Treatment%20In%20mRCC%20Patients%20"
        }, 
        "number_of_groups": "2", 
        "official_title": "Prospective Study To Analyse The Characteristics Of Patient Achieving Complete Remission With Sunitinib In mRCC And Identify Potential Predictive Factor Of Complete Remission vs Patients Not In Complete Remission Treated With Sunitinib", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare characteristics of mRCC patients with CR versus mRCC patients without CR with Sutent, in order to identify factors associated with remission", 
            "measure": "Characteristics of study patients", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To describe if mRCC patients with CR maintain or discontinue Sutent", 
                "measure": "mRCC patients with CR", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 36 months"
            }, 
            {
                "description": "To identify biomarkers (FGF, IL8, VEGF...) of complete response and relapse/progression if occurs", 
                "measure": "Presence (rate) or Absence of blood biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 36 months"
            }, 
            {
                "description": "To compare the biomarkers previously identified between the 2 arms (patients with CR versus patients without CR)", 
                "measure": "Presence (rate) or Absence of blood biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 36 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}